| Earnings Estimates Moving Higher for TransMedics (TMDX): Time to Buy? |
TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-05-15 17:21:05 |
Czytaj oryginał (ang.) |
| What Makes TransMedics (TMDX) a New Buy Stock |
TransMedics (TMDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-15 17:05:14 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| 2 Brilliant Stocks to Buy With $200 and Hold for 5 Years |
While being an innovative company doesn't guarantee superior long-term returns, it doesn't hurt those chances either. In fact, when a corporation is making important breakthroughs and boasts significant growth prospects in its industry, that could translate to above-average stock market performances over five years or more. |
fool.com |
2025-05-14 08:51:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Shareholders to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-13 14:00:00 |
Czytaj oryginał (ang.) |
| TransMedics Group Stock Is Up 81% in 2025. Can It Climb Even Higher? |
Shares of TransMedics Group (TMDX 6.54%) recently bounded higher in response to a first-quarter earnings report that was a lot better than investors were expecting. Downward revenue guidance revisions and unwanted attention from short-sellers pushed the stock down late last year, but things are looking up. |
fool.com |
2025-05-13 09:18:00 |
Czytaj oryginał (ang.) |
| TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-11 14:00:00 |
Czytaj oryginał (ang.) |
| TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down |
Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance. |
zacks.com |
2025-05-09 17:05:40 |
Czytaj oryginał (ang.) |
| Why TransMedics Stock Is Skyrocketing Today |
Shares of next-generation transplant technology platform TransMedics (TMDX 21.72%) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence. |
fool.com |
2025-05-09 16:42:32 |
Czytaj oryginał (ang.) |
| TransMedics: Exceptional Q1 Undermines The Short Narrative |
TransMedics reported extremely strong Q1 results, alleviating concerns from a weak Q3 2024 and a short attack in January. The company continues to expand its logistics capabilities and should see a boost from new heart and lung devices later in the year. While new perfusion devices are set to enter the market, TransMedics' competitive positioning appears to be extremely strong. |
seekingalpha.com |
2025-05-09 13:48:31 |
Czytaj oryginał (ang.) |
| TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript |
TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President & Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Bill Plovanic - Canaccord Justin Wang - Morgan Stanley Chris Pasquale - Nephron Research Suraj Kalia - Oppenheimer David Rescott - Baird Mike Matson - Needham & Company Josh Jennings - TD Cowen Operator Good afternoon, and welcome to TransMedics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-09 02:40:24 |
Czytaj oryginał (ang.) |
| Compared to Estimates, TransMedics (TMDX) Q1 Earnings: A Look at Key Metrics |
The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-09 00:00:39 |
Czytaj oryginał (ang.) |
| TransMedics (TMDX) Tops Q1 Earnings and Revenue Estimates |
TransMedics (TMDX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.35 per share a year ago. |
zacks.com |
2025-05-08 22:56:10 |
Czytaj oryginał (ang.) |
| TransMedics Reports First Quarter 2025 Financial Results |
ANDOVER, Mass. , May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-08 14:00:00 |
Czytaj oryginał (ang.) |
| 3 Mid-Cap Medical Stocks Outperforming the Market |
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. |
marketbeat.com |
2025-05-06 16:50:17 |
Czytaj oryginał (ang.) |
| TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-06 14:00:00 |
Czytaj oryginał (ang.) |
| Insights Into TransMedics (TMDX) Q1: Wall Street Projections for Key Metrics |
Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-05-05 14:21:28 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect |
NEW YORK, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-04 14:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation |
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX. |
accessnewswire.com |
2025-05-01 14:00:00 |
Czytaj oryginał (ang.) |
| TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
ANDOVER, Mass. , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. |
prnewswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| TransMedics Stock Plunges 57.5% in Three Months: What's Next? |
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance. |
zacks.com |
2024-12-13 15:21:25 |
Czytaj oryginał (ang.) |
| TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
ANDOVER, Mass. , Dec. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 9, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 20,612 shares of its common stock and an aggregate of 13,576 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. |
prnewswire.com |
2024-12-12 18:05:00 |
Czytaj oryginał (ang.) |
| Is TransMedics Stock a Buy Before 2025? |
In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below. |
fool.com |
2024-12-12 05:31:00 |
Czytaj oryginał (ang.) |
| 2 Healthcare Stocks to Buy Hand Over Fist and 1 to Avoid |
I've long viewed healthcare as one of the best sectors for long-term investors because everybody requires healthcare products and services sooner or later. With aging populations in the U.S. and other major countries, the demand will almost certainly increase over the next decade and beyond. |
fool.com |
2024-12-11 07:50:00 |
Czytaj oryginał (ang.) |
| Down Over 60%, Is TransMedics Stock a Buy on the Dip? |
TransMedics Group (TMDX 3.03%) was a top-performing stock that more than doubled in value during the months between the end of 2023 and late August. |
fool.com |
2024-12-08 06:33:00 |
Czytaj oryginał (ang.) |
| Why Transmedics Group Stock Plummeted 21% This Week |
Shares of Transmedics Group (TMDX 2.13%) sank over 20% this week, according to data from S&P Global Market Intelligence. The organ transplant disrupter announced a CFO transition and reduced the range for its full-year 2024 guidance, indicating slowing revenue growth. |
fool.com |
2024-12-06 17:26:41 |
Czytaj oryginał (ang.) |
| TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024 |
TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance. The company faces near-term challenges, but long-term growth prospects remain strong. The CEO suggested a temporary pause in growth at the Piper Sandler conference this week, with stronger performance expected in 2H 2025, driven by clinical data from heart and lung programs. |
seekingalpha.com |
2024-12-04 10:00:00 |
Czytaj oryginał (ang.) |
| TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm |
SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-transmedics-group-inc-investigation-tmdx.html You can also contact attorneys J.C. |
prnewswire.com |
2024-12-03 23:07:00 |
Czytaj oryginał (ang.) |
| Why TransMedics Stock Plummeted Today |
Shares of leading organ transplant platform TransMedics (TMDX -15.43%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence. |
fool.com |
2024-12-03 14:39:00 |
Czytaj oryginał (ang.) |
| Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. |
benzinga.com |
2024-12-03 10:12:42 |
Czytaj oryginał (ang.) |
| TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook |
ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. |
prnewswire.com |
2024-12-02 18:05:00 |
Czytaj oryginał (ang.) |
| Is TMDX Stock a Buy, Sell or Hold at a P/S Multiple of 5.02X? |
TransMedics is facing a softness in demand for transplant services in the United States. Moreover, rising costs raise concern. |
zacks.com |
2024-11-27 14:30:24 |
Czytaj oryginał (ang.) |
| TransMedics to Host Investor & Analyst Day on December 10, 2024 |
ANDOVER, Mass. , Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET. |
prnewswire.com |
2024-11-26 18:05:00 |
Czytaj oryginał (ang.) |
| 1 Top Growth Stock Down 56% to Buy After Its Recent Pullback |
In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below. |
fool.com |
2024-11-26 06:02:00 |
Czytaj oryginał (ang.) |
| 2 Hypergrowth Stocks That Are Screaming Buys in November |
2 Hypergrowth Stocks That Are Screaming Buys in November |
fool.com |
2024-11-23 06:10:00 |
Czytaj oryginał (ang.) |
| TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference |
ANDOVER, Mass. , Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. |
prnewswire.com |
2024-11-19 18:05:00 |
Czytaj oryginał (ang.) |
| TransMedics: Long-Term Thesis Hasn't Changed At All |
TMDX's Q3 revenue miss and margin contraction are short-term issues; long-term growth potential remains strong with management's guidance of 4,000 transplants this year and 10,000 in 3-5 years. High expectations led to a stock price drop, but management's clear communication on seasonal trends and market share stability supports the long-term thesis. TMDX is undervalued compared to peers like Intuitive Surgical and PROCEPT BioRobotics, with significant revenue growth potential and a unique market position. |
seekingalpha.com |
2024-11-19 13:27:51 |
Czytaj oryginał (ang.) |
| Is TransMedics Group Stock a Buy? |
This organ transplant specialist is down, but still has plenty of signs of life. |
fool.com |
2024-11-15 10:15:00 |
Czytaj oryginał (ang.) |
| TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade) |
TransMedics' Q3 results were weak, with revenue declining sequentially due to US transplant volume headwinds and scheduled aircraft maintenance. While the growth of TransMedics' current business is likely to continue moderating, there remain large opportunities internationally and in other organs. This is highlighted by the fact that TransMedics reiterated its longer-term transplant volume target, despite current weakness. |
seekingalpha.com |
2024-11-12 12:14:20 |
Czytaj oryginał (ang.) |